HC Wainwright Equities Analysts Lower Earnings Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Equities researchers at HC Wainwright lowered their FY2026 earnings per share estimates for shares of G1 Therapeutics in a research report issued on Thursday, May 2nd. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of $0.72 for the year, down from their prior estimate of $0.76. HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.64) per share.

Several other equities analysts also recently issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of G1 Therapeutics in a research report on Wednesday.

G1 Therapeutics Trading Up 1.1 %

Shares of GTHX opened at $4.49 on Friday. The stock has a fifty day moving average price of $3.90 and a two-hundred day moving average price of $3.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.45 and a current ratio of 3.87. G1 Therapeutics has a 52-week low of $1.08 and a 52-week high of $5.00. The company has a market cap of $234.87 million, a price-to-earnings ratio of -7.24 and a beta of 1.71.

G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Wednesday, May 1st. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $14.48 million for the quarter, compared to the consensus estimate of $15.21 million. G1 Therapeutics had a negative return on equity of 67.50% and a negative net margin of 36.40%. During the same quarter last year, the business earned ($0.53) EPS.

Insider Activity

In other news, insider Rajesh Malik sold 28,600 shares of G1 Therapeutics stock in a transaction on Monday, February 12th. The stock was sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the sale, the insider now directly owns 169,938 shares of the company’s stock, valued at approximately $785,113.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 8.23% of the company’s stock.

Institutional Investors Weigh In On G1 Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GTHX. Financial Advocates Investment Management acquired a new stake in shares of G1 Therapeutics during the fourth quarter worth $39,000. Capstone Investment Advisors LLC acquired a new stake in shares of G1 Therapeutics during the fourth quarter worth $76,000. Algert Global LLC acquired a new stake in shares of G1 Therapeutics during the third quarter worth $98,000. Curi Wealth Management LLC grew its stake in shares of G1 Therapeutics by 17.8% during the third quarter. Curi Wealth Management LLC now owns 70,742 shares of the company’s stock worth $102,000 after purchasing an additional 10,700 shares during the period. Finally, Jump Financial LLC acquired a new stake in shares of G1 Therapeutics during the fourth quarter worth $105,000. 24.21% of the stock is owned by institutional investors and hedge funds.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.